Minerva Neurosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
NERV Nasdaq 2836 www.minervaneurosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Minerva Neurosciences, Inc.

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs - Jun 1st, 2026 2:05 pm
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy - May 20th, 2026 10:00 am
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - May 20th, 2026 7:35 am
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference - May 18th, 2026 2:05 pm
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates - May 5th, 2026 6:00 am
NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences - Apr 13th, 2026 3:08 am
Minerva Announces Leadership Transition - Apr 2nd, 2026 2:05 pm
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia - Mar 31st, 2026 2:05 pm
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 - Mar 25th, 2026 2:05 pm
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms - Mar 20th, 2026 11:02 pm
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - Mar 12th, 2026 5:00 am
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates - Mar 11th, 2026 5:00 am
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference - Mar 4th, 2026 5:00 am
Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most - Feb 16th, 2026 3:45 am
Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia - Feb 4th, 2026 12:07 am
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 - Jan 26th, 2026 5:00 am
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors - Nov 19th, 2025 6:30 am